{"prompt": "['MC1575', '18', 'Amendment 2', '4.0', 'STUDY CALENDAR', '4.1', 'Test Schedule', 'Active Treatment', 'Prior to', '28 days', '14 days', '7 days', 'Cycle 1', 'Day 1 of', 'prior to', 'prior to', 'prior to', 'subsequent', 'Every 2', 'End of', 'Tests and procedures\u00b9', 'registration', 'registration', 'registration', 'D1', 'D3', 'D10\u00b2', 'cycles3', 'months', 'Treatment', 'Window', '3 days', '7 days', '14 days', 'Clinical Procedures', 'Vital signs, history (including personal/family history for prolonged QTc) and exam,', 'X', 'X', 'X', 'X', 'weight, PS', 'Height', 'X', 'Review of concurrent medications', 'X', 'X', 'Pregnancy test\u00b3', 'X', 'Blood pressure monitoring\u00b0', 'X', 'X', 'Adverse event assessment', 'X', 'X', 'X', 'Consultation with endocrinologist, cardiologist, or nephrologist for blood pressure', 'X', 'X', 'management', \"Hematology: CBC/diff'\", 'X', 'X', 'X', 'Chemistry Panel', 'X', 'X', 'X', 'TSH', 'X', 'X', '24 hr urine catecholamine and metanephrines', 'X', 'X', 'Plasma fractionated metanephrines', 'X', 'X', \"Urinalysis'\", 'X', 'X', 'Urine protein/creatinine ratio', 'X', 'X', 'Genetic counseling and testing at discretion of patient and counselor10', 'X', '1', 'All tests and procedures are clinically indicated, unless noted with an R to indicate funding by research', '2', 'May be omitted at discretion of treating provider and replaced with telephone call contact.', '3', 'If patient is tolerating treatment well, return visits may be performed over the phone for non-imaging cycles (starting with cycle 3, 5, 7 etc.). During these phone visits the patient', 'status, treatment information, and Adverse Event Assessments must be assessed and recorded. Labs may be done locally and transmitted', 'to', 'Mayo', 'Clinic.', '4', 'Concurrent/concomitant medications are reviewed every cycle. Only requested medications are recorded in the study case report forms.', '5', 'For women of childbearing potential only. Must be done 7 days prior to registration', '6', 'Note: 1) daily monitoring of blood pressure is REQUIRED and must be recorded in patient diaries throughout the entire duration of therapy; 2) any systolic BP >150 mm Hg', 'and/or diastolic BP >100 mm Hg must be brought to the attention of treating provider <24h after noted; 3) any systolic BP >200 mm Hg and/or diastolic BP >110 mm HG', 'should prompt immediate cessation of lenvatinib therapy maintained until remediation to <150 mm Hg systolic is accomplished.', '7', 'Must include: hemoglobin (hgb), MCV, leukocyte count, neutrophils (ANC), monocyte count, lymphocyte count, and platelet count (PLT)', '8', 'AST, alk phos, total bilirubin (direct if TBili is elevated), creatinine (and calculated creatinine clearance), albumin, glucose, calcium (Ca), sodium (Na), potassium (K),', 'magnesium (Mg), phosphorus (P), uric acid, LDH,', '9', 'Urinalysis for protein, glucose, blood', '10', 'Only if not performed previously (optional); can be performed anytime during study. Testing should include SDHD, SDHB, RET, VHL, neurofibromatosis type-1 genes.', 'Protocol Version Date:16Aug2018']['MC1575', '19', 'Amendment 2', 'Active Treatment', 'Prior to', '<28 days', '14 days', '7 days', 'Cycle 1', 'Day 1 of', 'prior to', 'prior to', 'prior to', 'subsequent', 'Every 2', 'End of', 'Tests and procedures 1', 'registration', 'registration', 'registration', 'D1', 'D3', 'D10\u00b2', 'cycles\u00b3', 'months', 'Treatment', 'Window', '3 days', '7 days', '14 days', 'PET-CT or CT (Chest, Abdomen and pelvis), or MRI abdomen/MRI neck, if needed', 'X', 'X', 'x11', 'ECG', 'X', 'x12', '2D-ECHO', 'X', 'Blood or Tissue-Analysis performed by Research Lab', 'Optional tissue sample for correlatives (see Section 17.0)13', 'X', 'Optional research blood will be collected under IRB 13-00583814', 'X', 'Quality of Life assessment', 'Patient Questionnaire Booklet: EQ-5D-5L/FACT-G', 'X15', 'X', 'Cycle = 28 days', '4.2', 'Event Monitoring/Survival Follow-up', 'Event Monitoring Phase', 'q. 3 months', 'After PD', 'until PD', 'At PD', 'q. 6 months', 'Death', 'New Primary', 'Event Monitoring', 'X', 'X', 'X', 'X', 'At each occurrence', '1. If a patient is still alive 5 years after registration, no further follow-up is required.', '11', 'Repeat imaging needed within 4 weeks of documentation of disease recurrence per RECIST (see Section 11.0).', '12 Only for Cycle 2 and 3', '13', 'Request archived tissue if patient has consented to release of tissue.', '14', 'Contact', 'for specifics.', '15', 'Baseline booklet must be completed after patient has consented and prior to first treatment', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}